Refine by
Stem Cell Research Articles & Analysis: Older
25 news found
In this free webinar, learn about the challenges in maintaining reliability, reproducibility and consistency in induced pluripotent stem cell (iPSC) cultures. Attendees will be introduced to a novel cell line restoration method supported by high-throughput single-cell cloning technologies. The featured speakers will explore the ...
Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations. ...
In turn, this empowers researchers to gain a deeper insight into the role of these markers in diverse cell types and biological processes. ...
Melissa Carpenter, PhD, Chief Scientific Officer, ElevateBio, Regenerative Medicine Author of over 50 peer-reviewed articles and inventor of 34 issued patents, Melissa Carpenter has been pioneering the field of stem cell-derived cell therapies for the past 25 years. She started her career at CytoTherapeutics (became StemCells, Inc), where she ...
“After IV delivery, the cells migrate to the lungs for local therapeutic benefit. We expect the anti-inflammatory nature of these mesenchymal stem cells to have a positive impact in ARDS because of the interaction of the Neurokinin-1 receptors with Substance P, a neuropeptide that has long been known to be a primary mediator of ...
[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, announces the designation of a new reimbursement code for the CardiAMP® Cell Therapy procedure to transplant autologous bone marrow cells to treat heart failure from the U.S. ...
The CardiAMP Cell Therapy Heart Failure Trial is the first multicenter clinical trial of a stem cell therapy to prospectively screen for stem cell therapeutic potency in order to improve patient outcomes. CardiAMP Cell Therapy incorporates three proprietary elements not previously utilized in ...
This newly released paper, titled “Perspective: Why and how to use the body’s own stem cells for regeneration in musculoskeletal disorders: a primer“, was published in the Journal of Orthopaedic Surgery and Research (J Orthop Surg Res 17, 36 (2022): https://doi.org/10.1186/s13018-022-02918-8). The publication provides an ...
Vancouver, BC, Canada - November 30, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, is pleased to announce a research agreement with the University Health Network (UHN). Through this collaboration, Aspect Biosystems will combine its bioprinting technology with UHN’s ...
Laurencin is dedicated to important social justice research and initiatives, including raising awareness of, and addressing, racial and ethnic health disparities. ...
ByAlkermes
– Oct. 29, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the publication of the peer-reviewed manuscript, “Co-grafts of Human Stem Cell-Derived Retina Organoids and Retinal Pigment Epithelium for Retinal Reconstruction in Immunodeficient ...
StemBioSys CEO Bob Hutchens made the announcement, noting “Dr. Loring brings extraordinary research credentials to our Scientific Advisory Board. Among the many accomplishments of her career, she has led hallmark research studies on differentiating human induced pluripotent stem cells (iPSCs) into neurons that have ...
Regeneus has partnered with the Allogeneic STEM cell manufacturing Programme (ASTEM) to investigate the status of a novel genomic biomarker within their adipose donor banks. ...
Hans Clevers, Xilis is based on decades of biomedical, oncology, and stem cell research by its three co-founders. Dr. Clevers, a Breakthrough Prize winner, is the inventor and pioneer of the organoid technology. ...
Today, French cell therapy company TreeFrog Therapeutics released data showing the mass production of human induced pluripotent stem cells (hiPSC) produced with their proprietary C-Stem™ technology in 10L bioreactors at the 2021 Annual Meeting of the International Society for Stem ...
Hypoxia maintains the niche where stem cells stay in optimal condition that benefits the self-renewal capacities of human embryonic, mesenchymal, hematopoietic and neural stem cells. ...
ByBaker
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, will be presenting at the Fifth Annual Cell Surgical World Conference in Beverly Hills this Saturday, June 2. Dr. Comella is, to the Company’s best knowledge, one of the ...
Heartcel, Celixir’s lead investigational cardiac regenerative medicine, is a tissue engineered medicine comprising allogeneic (off-the-shelf) immunomodulatory progenitor (iMP) cells and is designated as an advanced therapeutic medicinal product (ATMP) by the European Medicines Agency. iMP cells are a novel cell type engineered to reduce ...
Cell Therapy Ltd. (CTL) today announced the granting of the Japan license for its innovative cardiac regeneration medicine, Heartcel (immuno-modulatory progenitor [iMP] cells) to Daiichi Sankyo. ...
SAN FRANCISCO, CA--(Marketwired - Jun 2, 2015) - US Equity Holdings announced today that it has secured funding to launch Aelan Cell Technologies, a biotech startup engaged in the research, discovery, development and commercialization of innovative biomedical technologies and diagnostic tools for the advancement of human health and longevity. ...